Abbott Laboratories (NYSE:ABT) ranks among the best most active stocks to buy right now. Following encouraging results from Abbott Laboratories (NYSE:ABT)’s FreeDM trial, Benchmark reiterated a Buy rating and $145 price target for the company’s shares on March 13. In comparison to individuals using whole blood glucose meters with fingerstick blood samples, the trial demonstrated that patients with Type 2 diabetes on basal insulin therapy who employed FreeStyle Libre continuous glucose monitoring technology ...

Two fields in particular draw attention when we look at Abbott. The company’s FreeStyle Libre product is a leader in the continuous glucose monitoring (CGM) market, a vital technology in controlling and managing diabetes. Abbott’s product boasts that it is the leading CGM brand in the US. Abbott’s cardiovascular products include devices to manage such conditions as heart failure, irregular heartbeat, and mitral regurgitation.The first company we’ll look at, Abbott Laboratories, was founded in 1888 – and has ...

Group 1: Investment Opportunities in Healthcare - Investing in dividend stocks from the healthcare industry can provide income and help manage tax obligations [1] - The healthcare sector encompasses a wide range of opportunities, including drug manufacturers, medical device manufacturers, and hospital suppliers [2] - Singapore's healthcare masterplan indicates investment opportunities in promoting healthier lifestyles and improving access to affordable healthcare services [3] Group 2: Shift in Healthcare Delivery - The Ministry of Health's approach emphasizes prevention and healthier lifestyles to reduce chronic diseases, benefiting companies like Apple with health-monitoring devices [4] - The pandemic has accelerated the decentralization of healthcare, focusing on home-based monitoring and local health hubs to enhance accessibility and reduce costs [7] - Companies like Abbott Laboratories are capitalizing on the demand for continuous glucose monitoring systems, with significant revenue growth [8] Group 3: Market Growth and Government Support - Singapore's healthcare market is projected to reach S$68.7 billion by 2029, driven by an aging population [11] - The government's healthcare budget is expected to rise to S$30 billion by 2030, creating opportunities for private companies to meet healthcare needs [12] - The structural shift in demographics presents fertile ground for investment in the healthcare sector [12]

Core Insights - Medtronic plc (MDT) has launched the MiniMed Go Smart MDI system with the Simplera sensor in Europe, integrating data from the InPen smart insulin pen into a single mobile app for diabetes management [1][3] Company Developments - Medtronic's Diabetes business is set to be separated and operate as MiniMed, with an IPO planned for December 2025, aiming for completion by the end of 2026 [2] - The MiniMed Go system is approved for individuals aged seven and older with insulin-requiring diabetes, and for children aged two to six under adult supervision, with a gradual rollout starting this month [4] Product Features - The MiniMed Go Smart MDI system offers real-time insights, actionable dose alerts, and a built-in advanced dose calculator, designed to assist users managing diabetes with multiple daily injections [3] - Compatibility of the Instinct Go sensor by Abbott with MiniMed Go is pending CE mark approval, allowing users to choose between a seven-day or 15-day sensor [5] Industry Outlook - The global diabetes devices market is projected to reach $35.26 billion by 2025, with a CAGR of 7.7% through 2034, driven by increasing diabetes prevalence, obesity, and advancements in monitoring technology [7] Competitive Landscape - Insulet's Omnipod 5 Automated Insulin Delivery System has expanded into the Middle East, addressing high unmet needs in the region [8] - Abbott's FreeStyle Libre has established a leading position in the CGM market, while Tandem Diabetes Care reported over $1 billion in sales and is preparing for multiple product launches [10][11]

Core Insights - Abbott Laboratories has raised its quarterly dividend to $0.63, marking a 6.8% increase from the previous rate, with a free cash flow payout ratio of 60.4% [1][2] - The company has a consistent dividend growth streak of 13 years, with total annual payout increasing from $1.04 in 2016 to $2.36 in 2025, representing a 127% increase [1] - Despite a 9.8% decline in shares year-to-date, the current dividend yield of 2.14% is considered attractive for income investors [1] Dividend Growth - Abbott has increased its dividend for 13 consecutive years, with a compound annual growth rate of 9.2% over the past decade [1] - The recent quarterly increase from $0.59 to $0.63 continues the trend, although growth rates have moderated compared to earlier in the decade [1] - CEO Robert Ford reaffirmed the company's commitment to growing dividends during the recent earnings call [1] Cash Flow Coverage - In fiscal 2024, Abbott generated $8.56 billion in operating cash flow and $6.35 billion in free cash flow, with a 60.4% free cash flow payout ratio [1] - The payout ratio increased from 42.4% in 2022, reflecting both growing dividend commitments and declining cash generation due to reduced COVID-related testing revenue [1] - Quarterly free cash flow payout ratios showed volatility, with a peak of 110% in Q1 2025, but normalized in subsequent quarters [1] Profitability Metrics - Abbott maintains a 22% operating margin and a 14.7% profit margin, with a return on equity of 13.2%, supporting dividend sustainability [1] - The FreeStyle Libre glucose sensor recall, classified as a Class I recall, poses risks to profitability and may lead to litigation costs [1] - The medical devices segment showed a 12.3% growth in Q4, with strong performance from electrophysiology products [1] Forward Guidance - Management's guidance for 2026 includes an adjusted EPS of $5.55-$5.80, indicating approximately 10% growth at the midpoint [1] - Expected organic sales growth is projected at 6.5-7.5%, with annual margin expansion of 50-70 basis points [1] - The nutrition segment, which declined 8.9% in Q4, is anticipated to face challenges in the first half of 2026 before recovery [1] Valuation and Peer Comparison - Abbott's trailing P/E ratio is 30x, while the forward P/E is 20x, suggesting potential normalization as earnings grow [2] - Compared to Johnson & Johnson's 2.16% dividend yield and 46.6% payout ratio, Abbott's 63.8% payout ratio indicates less cushion but remains sustainable [2] - Institutional investors hold 81.7% of Abbott's shares, reflecting confidence in the company's long-term prospects despite current challenges [2]

Core Viewpoint - Abbott Laboratories' stock has recently declined following disappointing fourth-quarter results, but it remains attractive for dividend-seeking investors due to its strong core business segments [1]. Financial Performance - Abbott's fourth-quarter sales reached $11.5 billion, reflecting a 4.4% increase year-over-year, although this growth fell short of expectations [2]. - The company faced challenges in its nutrition and diagnostics segments, contributing to a sharp decline in stock price after the earnings release [2]. Business Segment Analysis - The core medical device business showed resilience, achieving a 12.3% sales growth in the quarter, driven by a 14.5% increase in revenue from the diabetes care unit [3]. - Abbott's leadership in the continuous glucose monitoring (CGM) market, particularly with the FreeStyle Libre franchise, positions it well for future growth [3][4]. Growth Opportunities - Recent product expansions, including over-the-counter offerings like Libre Rio and Lingo, have broadened Abbott's addressable market in diabetes care [4]. - The structural heart segment, featuring devices like MitraClip and TriClip, is expected to continue driving growth [5]. Strategic Acquisitions - Abbott's acquisition of Exact Sciences for approximately $21 billion is set to transform its diagnostics business and provide significant growth opportunities [5]. - Exact Sciences is known for its Cologuard test for colorectal cancer and has developed new diagnostic products for early cancer detection, tapping into a growing market [6].

Core Viewpoint - Abbott Laboratories has demonstrated consistent dividend growth, raising its quarterly dividend to $0.63, marking a 6.8% increase and extending its streak of consecutive dividend increases to 52 years [2][9] Financial Performance - In 2024, Abbott generated $6.35 billion in free cash flow, significantly exceeding its $3.84 billion in dividend payments, resulting in a free cash flow payout ratio of 60.4% [3][5] - Operating cash flow reached $8.56 billion in 2024, an 18% increase from $7.26 billion in 2023, with capital expenditures maintained at approximately $2.2 billion annually, representing about 25% of operating cash flow [4] Balance Sheet Strength - Abbott has reduced its total debt from $15.3 billion at the end of 2024 to $12.9 billion by Q3 2025, a 15% decrease, with a debt-to-equity ratio of 0.25x, down from 0.61x in 2020 [6] - Shareholder equity has increased from $32.8 billion in 2020 to $51.0 billion in Q3 2025, with retained earnings at $49.1 billion, indicating a robust balance sheet conducive to sustaining dividends [7] Business Diversification - Abbott's revenue streams are diversified, with medical devices growing by 12.5% in Q3 2025, driven by products like FreeStyle Libre, which generated $2 billion in quarterly revenue [8][9]

Core Insights - Abbott has launched Libre Assist, a new feature within the Libre app aimed at helping individuals with diabetes make informed food choices by predicting glucose impacts before meals [1][6][8] - The feature utilizes a color-coded rating system to indicate the potential glucose impact of foods, enhancing decision-making for users [2][7] - Libre Assist integrates generative AI to provide personalized meal guidance and confirms glucose effects using data from Abbott's continuous glucose monitoring (CGM) systems [4][6][8] Product Features - Libre Assist offers in-the-moment meal guidance by allowing users to input food data through photos or text descriptions, predicting glucose impact with a color-coded system: green for minor, yellow for moderate, and orange for major [7] - After meals, the app provides personalized feedback based on actual glucose data from the Libre CGM systems, helping users understand their unique responses to different foods [7][8] - The feature is available at no additional cost within the Libre app, requiring no separate subscription or prescription [8][9] Market Context - Abbott's FreeStyle Libre technology has been a leader in diabetes care for over a decade, currently used by more than 7 million people in over 60 countries [9] - The launch of Libre Assist is positioned as a significant advancement in diabetes management, addressing the need for more proactive tools beyond traditional food logging apps [2][8]

分组1 - The S&P 500 has shown resilience after flirting with bear market territory earlier this year, making healthcare stocks a strong consideration for potential investment in a bear market [1] - The healthcare sector is characterized by companies that tend to perform well during both economic upturns and downturns, with Johnson & Johnson and Abbott Laboratories highlighted as excellent stocks to buy in a bear market [2] 分组2 - Johnson & Johnson is a diversified healthcare leader with a strong presence in pharmaceuticals and medical technology, generating consistent revenue and profits even in weak economic conditions [4][5] - The company holds the highest credit rating, indicating financial stability, and is recognized as a Dividend King with 63 consecutive years of dividend increases, showcasing its ability to maintain payouts through various economic cycles [6] - Abbott Laboratories also exhibits strong diversification across medical devices, nutrition, diagnostics, and pharmaceuticals, allowing it to navigate challenging times effectively [7] - Abbott's growth prospects are particularly promising in diabetes care, with its FreeStyle Libre continuous glucose monitoring devices driving significant growth, and recent acquisitions aimed at expanding into the cancer diagnostic market [8]

Industry Overview - Asia is projected to become the world's fastest-growing healthcare market, reaching US$5 trillion by 2030, driven by aging populations and a growing middle class [1] - The increasing demand for healthcare products and services is expected to benefit healthcare providers, health-tech innovators, and health-related infrastructure across the region [1][13] Raffles Medical Group (SGX: BSL) - Raffles Medical Group reported a revenue growth of 3.5% year-on-year to S$378.4 million for the first half of 2025 [2] - The Raffles Health Insurance segment saw a revenue increase of 10% year-on-year to S$94.9 million, while Hospital Services experienced a gain of 3.8% year-on-year to S$174 million [2] - Profits rose by 5% year-on-year to S$32.5 million, primarily driven by Hospital Services segment profits increasing by 24.3% year-on-year to S$17.7 million [3] - The company is expanding its presence in China through strategic partnerships with Shanghai Renji Hospital and Chongqing's First Affiliated Hospital [4] - RMG has a trailing price-to-earnings (PE) ratio of over 29, indicating investor optimism regarding its future growth [4][5] Abbott Laboratories (NYSE: ABTT) - Abbott Laboratories reported a 6.9% year-on-year revenue gain to US$11.4 billion for the third quarter of 2025 [6] - The diabetes care medical devices segment contributed significantly, with sales growth of 19.3% year-on-year to US$2 billion, driven by the success of the FreeStyle Libre continuous glucose monitors [7] - Abbott launched new products in India, including the FreeStyle Libre 2 Plus and AVEIR™ DR, to capture the growing demand for medical devices in Asia [8] - The company maintains a healthy dividend yield of 1.9% and a PE ratio of 16, reflecting solid fundamentals [9] ParkwayLife REIT (SGX: C2PU) - ParkwayLife REIT experienced an 8.2% year-on-year increase in gross revenue to S$117.3 million for the first nine months of 2025 [10] - Net property income rose by 8.1% year-on-year to S$110.7 million, while distribution per unit (DPU) increased by 2.3% year-on-year to S$0.1156 [10] - Growth is attributed to step-up lease agreements and acquisitions, including nursing homes in France and Japan [11] - The REIT has a healthy gearing of 35.8%, well below the regulatory limit, indicating a strong balance sheet [12] Investment Opportunities - The Asia healthcare boom represents a long-term market shift rather than a cyclical upswing, driven by increased purchasing power and an aging population [13] - The three highlighted companies tap into different aspects of the healthcare value chain, presenting early investment opportunities in resilient stocks with structural upside [14]